نتایج جستجو برای: hiv vaccine
تعداد نتایج: 309384 فیلتر نتایج به سال:
A brief historical overview of anti-HIV vaccine approaches The identification of the human immunodeficiency virus as the causative agent of AIDS [1–4] was followed by intensive efforts to develop a vaccine against this pathogen. Initial vaccine approaches aimed at the elicitation of anti-viral neutralizing antibodies (NAbs). The sole target of anti-HIV NAbs is the viral envelope glycoprotein (E...
This paper reviews the English language literature on the safety, immunogenicity and effectiveness in children infected with the human immunodeficiency virus (HIV) of vaccines currently recommended by WHO for use in national immunization programmes. Immunization is generally safe and beneficial for children infected with HIV, although HIV-induced immune suppression reduces the benefit compared ...
Despite the availability of vertical transmission prevention, treatment, and immunisation programmes for better health outcomes, children are still infected affected by HIV/AIDS. Those accessing treatment either virally unsuppressed or have severe forms diseases, while others missed opportunities vaccination. HIV vulnerable to infections, re-hospitalisation, missing vaccinations. The study dete...
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
The world of human immunodeficiency virus (HIV) vaccines has suffered a baffling setback. The first trial of a vaccine designed to elicit strong cellular immunity has shown no protection against infection. More alarmingly, the vaccine appeared to increase the rate of HIV infection in individuals with prior immunity against the adenovirus vector used in the vaccine. A new study in this issue sug...
A guiding principle for HIV vaccine design has been that cellular and humoral immunity work together to provide the strongest degree of efficacy. However, three efficacy trials of Ad5-vectored HIV vaccines showed no protection. Transmission was increased in two of the trials, suggesting that this vaccine strategy elicited CD4+ T-cell responses that provide more targets for infection, attenuatin...
BACKGROUND Since the primary routes of human immunodeficiency type 1 (HIV-1) infection are across mucosal barriers, a randomized trial of canarypox virus-based vectors was conducted in 84 individuals, with delivery of vaccine by mucosal routes, and was accompanied by a detailed analysis of humoral, cellular, and mucosal immune responses. METHODS Over the course of 6 months, HIV-1-specific (vC...
A major obstacle to the design of a global HIV-1 vaccine is viral diversity. At present, data suggest that a vaccine comprising a single antigen will fail to generate broadly reactive B-cell and T-cell responses able to confer protection against the diverse isolates of HIV-1. While some B-cell and T-cell epitopes lie within the more conserved regions of HIV-1 proteins, many are localized to var...
INTRODUCTION The risk of poor vaccine immunogenicity and more severe influenza disease in HIV necessitate strategies to improve vaccine efficacy. METHODS A randomized, multi-centered, controlled, vaccine trial with three parallel groups was conducted at 12 CIHR Canadian HIV Trials Network sites. Three dosing strategies were used in HIV infected adults (18 to 60 years): two standard doses over...
The field of HIV prevention has indeed progressed in leaps and bounds, but with major limitations of the current prevention and treatment options, the world remains desperate for an HIV vaccine. Sadly, this continues to be elusive, because more than 30 years since its discovery there is no licensed HIV vaccine. Research aiming to define immunological biomarkers to accurately predict vaccine eff...
The National Institute of Allergy and Infectious Diseases (NIAID) decided recently to cancel plans for a large clinical trial of a candidate vaccine against HIV. The canceled clinical trial, known as PAVE 100, was originally proposed in January 2007 and designed to test whether the vaccine, which was developed by the NIAID’s Vaccine Research Center (VRC), could reduce acquisition of HIV infecti...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید